Skip to main content
Bioceltix S.A. logo

Bioceltix S.A. — Investor Relations & Filings

Ticker · BCX ISIN · PLBCLTX00019 LEI · 259400QZD5JYK8SLZU51 WAR Manufacturing
Open in API
Filings indexed 270 across all filing types
Latest filing 2022-05-24 Board/Management Inform…
Country PL Poland
Listing WAR BCX

About Bioceltix S.A.

https://bioceltix.com/en/

Bioceltix S.A. is a biopharmaceutical company that develops stem cell-based medicinal products for veterinary use. The company focuses on creating therapies that utilize Mesenchymal Stem Cells (MSCs) as the active pharmaceutical ingredient. Its product pipeline is aimed at treating immunological and inflammatory conditions in companion animals, including dogs, cats, and horses. A key area of development includes treatments for conditions such as atopic dermatitis in dogs and degenerative joint disease.

Recent filings

Filing Released Lang Actions
Sprawozdanie z działalności Rady Nadzorczej
Board/Management Information Classification · 1% confidence The document is titled "Sprawozdanie z działalności Rady Nadzorczej BIOCELTIX S.A. ... za rok obrotowy 2021" (Report on the activities of the Supervisory Board of BIOCELTIX S.A. ... for the financial year 2021). This report specifically details the Supervisory Board's assessment of the Financial Statement, the Management Board's activity report, and the proposal for covering the loss for the 2021 financial year. This content aligns perfectly with the function of a Supervisory Board report, which often accompanies or precedes the formal Annual Report (10-K) or Audit Report (AR) by providing oversight and recommendations regarding those primary documents. Since it is a comprehensive report detailing the board's activities and evaluations for the full year, it is best classified as an Audit Report / Information (AR), as it focuses heavily on the audit/review of the financial statements and management report, rather than being the full 10-K or just a brief announcement (RPA/RNS). The length (11,392 chars) confirms it is a substantial report, not a mere announcement.
2022-05-24 Polish
Uzupełnienie dokumentacji na Zwyczajne Walne Zgromadzenie Akcjonariuszy zwołane na dzień 15 czerwca 2022 roku o sprawozdanie Rady Nadzorczej - Content (PL)
Report Publication Announcement Classification · 1% confidence The document text is very short (487 characters) and explicitly states that it is supplementing a previous report regarding the convening of an Ordinary General Meeting (Zwyczajne Walne Zgromadzenie Akcjonariuszy) and that the Supervisory Board's report ('sprawozdanie z działalności Rady Nadzorczej') is being provided 'w załączeniu do niniejszego raportu bieżącego' (attached to this current report). This structure—a brief announcement referencing an attached or linked document that is the main subject—strongly indicates a Report Publication Announcement (RPA), as per the 'MENU VS MEAL' rule. The content relates to the AGM, but the document itself is the announcement of the attached material, not the AGM material or the report itself.
2022-05-24 Polish
Otrzymanie odpowiedzi w ramach procedury Porady Naukowej (Scientific Advice) od Europejskiej Agencji Leków dla kandydata na produkt leczniczy BCX-EM - Content (PL)
Regulatory Filings Classification · 1% confidence The document is a formal announcement from the Management Board ('Zarząd') of Bioceltix S.A. regarding receiving feedback (Scientific Advice) from the European Medicines Agency (EMA) concerning a drug candidate (BCX-EM) for treating arthritis in horses. This communication details the acceptance of the safety protocol and EMA's recommendations on the manufacturing process. This type of communication, which updates investors on significant regulatory interactions, legal/development risks, and scientific progress, fits best under general regulatory or investor-related announcements. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a specific management change (MANG), it falls under the category for miscellaneous regulatory or significant corporate updates. Given the content relates to regulatory feedback that significantly impacts the development risk, it is classified as a general Regulatory Filing (RNS), as it is a specific, non-standard announcement that doesn't fit the other precise categories like DIV, DIRS, or CAP. The document length is short (1469 chars), but it conveys substantive information rather than just announcing the publication of another document, thus avoiding the RPA classification.
2022-05-24 Polish
Informacja o liczbie akcji i głosów
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled 'INFORMACJA O LICZBIE AKCJI I GŁOSÓW' (Information on the Number of Shares and Votes) and explicitly references the convening of an Extraordinary General Meeting ('Nadzwyczajnego Walnego Zgromadzenia Akcjonariuszy'). It details the total number of shares and total votes available for that meeting. This content directly relates to the voting structure and share count relevant to a shareholder meeting, which aligns best with the Declaration of Voting Results & Voting Rights Announcements (DVA), as it provides the foundational data for voting rights, even if it precedes the actual vote results. It is not a full report (10-K, IR), an earnings release (ER), or a management change (MANG). Given the context of an upcoming EGM and the disclosure of total votes, DVA is the most appropriate fit.
2022-05-19 Polish
Klauzula informacyjna o przetwarzaniu danych osobowych
Proxy Solicitation & Information Statement Classification · 1% confidence The document is titled "KLAUZULA INFORMACYJNA O PRZETWARZANIU DANYCH OSOBOWYCH PRZEZ BIOCELTIX S.A. DLA AKCJONARIUSZY..." (Information Clause on Personal Data Processing by BIOCELTIX S.A. for Shareholders...). It extensively discusses the processing of personal data of shareholders and their representatives in connection with convening and conducting a General Meeting ("Walne Zgromadzenie" or "WZ"). This type of document, which provides detailed information regarding shareholder rights, data processing under GDPR (RODO), and procedures related to shareholder meetings, is typically associated with the materials required for soliciting proxies or providing essential information before a shareholder vote. The closest fit among the provided codes is 'Proxy Solicitation & Information Statement' (PSI), as it directly relates to the information provided to shareholders concerning their rights and participation in a meeting, which often precedes or accompanies proxy materials. It is not the AGM presentation itself (AGM-R), nor is it a formal regulatory filing like a 10-K or an Earnings Release (ER).
2022-05-19 Polish
Formularz głosowania przez pełnomocnika - wersja edytowalna
AGM Information Classification · 1% confidence The document is titled "FORMULARZ WYKONYWANIA PRAWA GŁOSU PRZEZ PEŁNOMOCNIKA" (Proxy Voting Form) and explicitly refers to instructions for voting at the "Zwyczajnym Walnym Zgromadzeniu" (Annual General Meeting - AGM) of BIOCELTIX S.A. scheduled for June 15, 2022. It contains detailed voting instructions for various resolutions, including the approval of the 2021 management report, financial statements, and granting discharge (absolutorium) to board members. This material is directly related to the proceedings and voting process of the AGM. Therefore, it classifies as AGM Information.
2022-05-19 Polish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.